141 related articles for article (PubMed ID: 19900802)
1. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V; Citterio G; Vitali G; Spreafico A; Scifo P; Borri A; Donadoni G; Rossoni G; Corti A; Caligaris-Cappio F; Del Maschio A; Esposito A; De Cobelli F; Dell'Acqua F; Troysi A; Bruzzi P; Lambiase A; Bordignon C
Eur J Cancer; 2010 Jan; 46(1):198-206. PubMed ID: 19900802
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW; Fiedler W; Desar IM; van Asten JJ; Marréaud S; Lacombe D; Govaerts AS; Bogaerts J; Lasch P; Timmer-Bonte JN; Lambiase A; Bordignon C; Punt CJ; Heerschap A; van Herpen CM
Clin Cancer Res; 2010 Feb; 16(4):1315-23. PubMed ID: 20145168
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Desar IM; van Herpen CM; van Asten JJ; Fiedler W; Marreaud S; Timmer-Bonte JN; ter Voert EG; Lambiase A; Bordignon C; Heerschap A; van Laarhoven HW
Eur J Radiol; 2011 Dec; 80(3):655-61. PubMed ID: 20863638
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours.
Zucali PA; Simonelli M; De Vincenzo F; Lorenzi E; Perrino M; Bertossi M; Finotto R; Naimo S; Balzarini L; Bonifacio C; Timofeeva I; Rossoni G; Mazzola G; Lambiase A; Bordignon C; Santoro A
Br J Cancer; 2013 Jan; 108(1):58-63. PubMed ID: 23169299
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V; Santoro A; Bennicelli E; Punt CJ; Citterio G; Timmer-Bonte JN; Caligaris Cappio F; Lambiase A; Bordignon C; van Herpen CM
Br J Cancer; 2009 Jul; 101(2):219-24. PubMed ID: 19568235
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Santoro A; Rimassa L; Sobrero AF; Citterio G; Sclafani F; Carnaghi C; Pessino A; Caprioni F; Andretta V; Tronconi MC; Finocchiaro G; Rossoni G; Zanoni A; Miggiano C; Rizzardi GP; Traversari C; Caligaris-Cappio F; Lambiase A; Bordignon C
Eur J Cancer; 2010 Oct; 46(15):2746-52. PubMed ID: 20708923
[TBL] [Abstract][Full Text] [Related]
7. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
Gregorc V; Zucali PA; Santoro A; Ceresoli GL; Citterio G; De Pas TM; Zilembo N; De Vincenzo F; Simonelli M; Rossoni G; Spreafico A; Grazia Viganò M; Fontana F; De Braud FG; Bajetta E; Caligaris-Cappio F; Bruzzi P; Lambiase A; Bordignon C
J Clin Oncol; 2010 May; 28(15):2604-11. PubMed ID: 20406925
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V; De Braud FG; De Pas TM; Scalamogna R; Citterio G; Milani A; Boselli S; Catania C; Donadoni G; Rossoni G; Ghio D; Spitaleri G; Ammannati C; Colombi S; Caligaris-Cappio F; Lambiase A; Bordignon C
Clin Cancer Res; 2011 Apr; 17(7):1964-72. PubMed ID: 21307147
[TBL] [Abstract][Full Text] [Related]
10. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Mammoliti S; Andretta V; Bennicelli E; Caprioni F; Comandini D; Fornarini G; Guglielmi A; Pessino A; Sciallero S; Sobrero AF; Mazzola G; Lambiase A; Bordignon C
Ann Oncol; 2011 Apr; 22(4):973-978. PubMed ID: 20855468
[TBL] [Abstract][Full Text] [Related]
11. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM; Calimeri T; Conte GM; Cattaneo D; Fallanca F; Ponzoni M; Scarano E; Curnis F; Nonis A; Lopedote P; Citterio G; Politi LS; Foppoli M; Girlanda S; Sassone M; Perrone S; Cecchetti C; Ciceri F; Bordignon C; Corti A; Anzalone N
Blood; 2019 Jul; 134(3):252-262. PubMed ID: 31118164
[TBL] [Abstract][Full Text] [Related]
12. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A; Pressiani T; Citterio G; Rossoni G; Donadoni G; Pozzi F; Rimassa L; Personeni N; Bozzarelli S; Rossoni G; Colombi S; De Braud FG; Caligaris-Cappio F; Lambiase A; Bordignon C
Br J Cancer; 2010 Sep; 103(6):837-44. PubMed ID: 20717115
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling.
Valentinis B; Porcellini S; Asperti C; Cota M; Zhou D; Di Matteo P; Garau G; Zucchelli C; Avanzi NR; Rizzardi GP; Degano M; Musco G; Traversari C
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547231
[TBL] [Abstract][Full Text] [Related]
14. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.
Corti A; Curnis F; Rossoni G; Marcucci F; Gregorc V
BioDrugs; 2013 Dec; 27(6):591-603. PubMed ID: 23743670
[TBL] [Abstract][Full Text] [Related]
15. NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Gregorc V; Cavina R; Novello S; Grossi F; Lazzari C; Capelletto E; Genova C; Salini G; Lambiase A; Santoro A
Oncologist; 2018 Oct; 23(10):1133-e112. PubMed ID: 30076277
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.
Lorusso D; Scambia G; Amadio G; di Legge A; Pietragalla A; De Vincenzo R; Masciullo V; Di Stefano M; Mangili G; Citterio G; Mantori M; Lambiase A; Bordignon C
Br J Cancer; 2012 Jun; 107(1):37-42. PubMed ID: 22644293
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
18. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.
Di Matteo P; Hackl C; Jedeszko C; Valentinis B; Bordignon C; Traversari C; Kerbel RS; Rizzardi GP
Br J Cancer; 2013 Jul; 109(2):360-9. PubMed ID: 23828516
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
[TBL] [Abstract][Full Text] [Related]
20. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
